Anxiety psychedelic and ketamine research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
52 registered studies are counted for anxiety. By compound: 22 psilocybin, 4 MDMA, 8 LSD, 3 DMT, 2 5-MeO-DMT and 18 ketamine. By registry status: 12 recruiting, 2 not yet recruiting, 2 enrolling by invitation, 5 active, not recruiting, 25 completed, 2 terminated, 3 withdrawn and 1 status not reported. By phase: 5 early phase 1, 7 phase 1, 24 phase 2, 2 phase 3, 4 phase 4 and 10 not reported. Reported start years run from 2004 (earliest) to 2026 (latest).
This page includes generalized anxiety disorder, social anxiety and anxiety linked to illness when the title names anxiety. Perioperative anxiety is not included. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 52 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 22 |
| MDMA | 4 |
| LSD | 8 |
| DMT | 3 |
| 5-MeO-DMT | 2 |
| Ketamine | 18 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 12 | 23% |
| Not yet recruiting | 2 | 4% |
| Enrolling by invitation | 2 | 4% |
| Active, not recruiting | 5 | 10% |
| Completed | 25 | 48% |
| Terminated | 2 | 4% |
| Withdrawn | 3 | 6% |
| Status not reported | 1 | 2% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Early Phase 1 | 5 | 10% |
| Phase 1 | 7 | 13% |
| Phase 2 | 24 | 46% |
| Phase 3 | 2 | 4% |
| Phase 4 | 4 | 8% |
| Not reported | 10 | 19% |
Countries
Country is taken from the study's linked research site. 0 of 52 records have no country on file. The top 10 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 35 | 67% |
| Switzerland | 6 | 12% |
| Argentina | 2 | 4% |
| Australia | 2 | 4% |
| Canada | 2 | 4% |
| Egypt | 1 | 2% |
| France | 1 | 2% |
| Italy | 1 | 2% |
| Jamaica | 1 | 2% |
| Poland | 1 | 2% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 22 |
| 2020 to 2023 | 15 |
| 2015 to 2019 | 6 |
| 2010 to 2014 | 3 |
| Before 2010 | 6 |
Study design
- 42 interventional and 10 observational studies.
- Median planned or actual enrolment is 41 participants (range 2 to 50,000, across 49 records that report it).
Registered studies
The 50 studies with the latest start dates, newest first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| Group Retreat Psilocybin Therapy for Healthcare Clinicians With Loss of Meaning in Their Work and Symptoms of Depression | NCT07565909 | Not yet recruiting | Phase 2 | 2026-06-01 | Psilocybin |
| Group Retreat Psilocybin Therapy for the Treatment of Anxiety and Depression in Patients With Metastatic Solid Tumors or Incurable Hematologic Malignancies | NCT07336238 | Active, not recruiting | Phase 2 | 2026-04-01 | Psilocybin |
| A Mechanistic Study to Assess a Single Dose of CYB003 in Participants With Depression and Anxiety | NCT06820723 | Recruiting | Phase 2 | 2025-11-01 | Psilocybin |
| Psilocybin-Assisted Psychotherapy in Cancer Patients With Adjustment Disorder | NCT07072728 | Recruiting | Phase 2 | 2025-10-01 | Psilocybin |
| Psilocybin-Assisted Therapy for Intergenerational Trauma | NCT06899165 | Recruiting | Phase 2 | 2025-08-28 | Psilocybin |
| TRIPS - Treatment to Improve Depression and/or Anxiety Using Psilocybin-assisted Psychotherapy in Cancer Survivors | NCT06801041 | Recruiting | Phase 2 | 2025-05-23 | Psilocybin |
| Retrospective Analyses of the Greenbrook Database Evaluating Mental Health Treatments | NCT06997549 | Recruiting | Not reported | 2025-05-15 | Ketamine |
| Safety, Tolerability, and Preliminary Efficacy of Psilocybin Oral Solution in Adults With Generalized Anxiety Disorder | NCT06969170 | Recruiting | Phase 2 | 2025-05-06 | Psilocybin |
| Effects of Intranasal Ketamine on Depression and Anxiety in Palliative Care Cancer Patients | NCT06665568 | Not yet recruiting | Early Phase 1 | 2025-04-01 | Ketamine |
| Assess the Utility of a Speech-based Machine Learning Algorithm to Predict Treatment Response to Psychiatric Interventions | NCT06823024 | Enrolling by invitation | Not reported | 2025-02-18 | Ketamine |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | NCT06809595 | Active, not recruiting | Phase 3 | 2025-01-29 | LSD |
| Efficacy of Sublingual 5-MeO-DMT for Reducing Anxiety and Depression in MCI | NCT06812221 | Completed | Phase 1 | 2024-12-15 | DMT, 5-MeO-DMT |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | NCT06741228 | Active, not recruiting | Phase 3 | 2024-12-11 | LSD |
| A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer | NCT06644170 | Completed | Phase 1 | 2024-11-19 | Psilocybin |
| Safety, Tolerability, and Efficacy of Sublingual Microdoses of 5-MeO-DMT for Depression and Anxiety | NCT06816667 | Completed | Phase 1 | 2024-10-21 | DMT, 5-MeO-DMT |
| Open-Label Psilocybin Study in Transdiagnostic Population | NCT06442423 | Recruiting | Phase 1 | 2024-10-17 | Psilocybin |
| Psilocybin-assisted Therapy for Alcohol Use Disorder | NCT06444243 | Status not reported | Phase 2 | 2024-09-01 | Psilocybin |
| Salivary Oxytocin as a Biomarker in Psychedelic Assisted Psychotherapy | NCT06557239 | Completed | Not reported | 2024-08-05 | LSD |
| Lysergic Acid Diethylamide (LSD) in Palliative Care | NCT05883540 | Recruiting | Phase 2 | 2024-06-09 | Psilocybin, LSD |
| A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD) | NCT06051721 | Completed | Phase 2 | 2024-05-10 | DMT |
| Psilocybin-Assisted Psychotherapy in Patients With Advanced Cancer on Maintenance Therapy | NCT06200155 | Recruiting | Phase 2 | 2024-04-16 | Psilocybin |
| PSilocybin for psYCHological and Existential Distress in PALliative Care (PSYCHED-PAL) | NCT04754061 | Active, not recruiting | Phase 1 | 2024-01-08 | Psilocybin |
| Ketamine-Assisted PsychoTherapy ViAbility in Treating Cancer-related Emotional Distress | NCT05344625 | Withdrawn | Early Phase 1 | 2023-10-31 | Ketamine |
| Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion | NCT06060210 | Completed | Phase 4 | 2023-10-29 | Ketamine |
| RIVER At Home Ketamine Protocols | NCT06070766 | Recruiting | Not reported | 2023-10-01 | Ketamine |
| Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer | NCT05847686 | Completed | Phase 1 | 2023-06-27 | Psilocybin |
| Ketamine Treatment Plans for Chronic Conditions | NCT06038409 | Recruiting | Not reported | 2023-01-01 | Ketamine |
| Esketamine Nasal Spray in Real-World Settings in Treatment-Resistant Depression | NCT07146503 | Recruiting | Not reported | 2022-11-01 | Ketamine |
| Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients With Pancreatic Cancer | NCT05086250 | Completed | Early Phase 1 | 2022-10-20 | Ketamine |
| Assessing the Efficacy of Micro-dosed Psilocybin on Reducing Anxiety & Depression Levels in Adults | NCT04989972 | Withdrawn | Phase 2 | 2022-09-15 | Psilocybin |
| Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD) | NCT05565352 | Enrolling by invitation | Not reported | 2022-09-01 | Ketamine |
| A Dose-Finding Study of MM-120 (LSD D-Tartrate) for the Treatment of Anxiety Symptoms | NCT05407064 | Completed | Phase 2 | 2022-08-24 | LSD |
| Social Anxiety MDMA-Assisted Therapy Investigation | NCT05138068 | Completed | Phase 2 | 2022-04-13 | MDMA |
| Tolerance and Potential Synergistic Effect of the Combination of Intranasal Esketamine and Non-selective MAOI | NCT05530668 | Completed | Not reported | 2022-04-11 | Ketamine |
| Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease | NCT04932434 | Completed | Phase 2 | 2021-08-15 | Psilocybin |
| Retrospective Observational Study of Intensity Effects in Psychedelic-assisted Treatment | NCT07164287 | Active, not recruiting | Not reported | 2020-06-01 | Psilocybin, LSD |
| A Retrospective Effectiveness Trial of Ketamine-Assisted Psychotherapy in Adult Patients Coping With Mental Health | NCT05604794 | Completed | Phase 4 | 2020-03-13 | Ketamine |
| Ketamine Infusion Therapy for the Treatment of PTSD in Paramedics | NCT03947099 | Completed | Not reported | 2019-05-02 | Ketamine |
| LSD Treatment in Persons Suffering From Anxiety Symptoms in Severe Somatic Diseases or in Psychiatric Anxiety Disorders | NCT03153579 | Completed | Phase 2 | 2017-06-23 | Psilocybin, LSD |
| Ketamine for Depression: An MRI Study | NCT02544607 | Completed | Phase 4 | 2016-03-01 | Ketamine |
| Ketamine Infusion for Adolescent Depression and Anxiety | NCT02579928 | Completed | Phase 4 | 2015-10-01 | Ketamine |
| MDMA-Assisted Psychotherapy for Anxiety Associated With a Life-Threatening Illness | NCT02427568 | Completed | Phase 2 | 2015-05-14 | MDMA |
| Ketamine Infusion for Social Anxiety Disorder | NCT02083926 | Completed | Early Phase 1 | 2015-01-02 | Ketamine |
| Phase 2 Pilot Safety Study of MDMA-assisted Therapy for Social Anxiety in Autistic Adults | NCT02008396 | Completed | Phase 2 | 2014-04-11 | MDMA |
| Oral Ketamine in the Treatment of Depression and Anxiety in Patients With Cancer | NCT01680172 | Terminated | Phase 2 | 2012-08-01 | Ketamine |
| Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma | NCT00979693 | Withdrawn | Phase 2 | 2012-01-01 | Psilocybin |
| Psilocybin Cancer Anxiety Study | NCT00957359 | Completed | Early Phase 1 | 2009-02-01 | Psilocybin |
| Ketamine as a Rapid Treatment for Post-traumatic Stress Disorder (PTSD) | NCT00749203 | Completed | Phase 2 | 2009-01-01 | Ketamine |
| Lysergic Acid Diethylamide (LSD)-Assisted Psychotherapy in People With Illness-related Anxiety | NCT00920387 | Completed | Phase 2 | 2008-02-01 | LSD |
| Psychopharmacology of Psilocybin in Cancer Patients | NCT00465595 | Completed | Phase 2 | 2007-04-01 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | LSD | DMT | 5-MeO-DMT | Ketamine
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Cancer and end-of-life distress | Obsessive-compulsive disorder | Eating disorders | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk